证券日报网讯1月12日，英威腾（002334）在互动平台回答投资者提问时表示，苏州英威腾3期项目是公 司基于未来中长期业务发展制定的规划产能建设。后续公司将根据项目进展及市场情况，稳步推进产能 落地，相关数据请以公司披露的信息为准。 ...

Investment Highlights - The company is rated as outperforming the industry with a target price of 70.61 yuan, corresponding to a 50x P/E for 2026, due to its unique position as a core supplier of guided equipment and ammunition systems [1] - The company is backed by Jiangxi Provincial Military Industry Holding Group and has a diverse product range including guided equipment, solid rocket engine power modules, and ammunition systems, which are scarce in the market [1] - Revenue is expected to grow by 15.8% year-on-year in 2024, reaching 1.204 billion yuan, with net profit attributable to shareholders increasing by 41.3% to 199 million yuan [1] - Global defense spending is projected to increase by 9.4% in 2024, reaching 2.7 trillion USD, with guided and ammunition equipment being key focus areas [1] Production and Trade Development - The company has received a contract worth 466 million yuan for a foreign trade product engine, indicating potential for long-term growth in special trade [2] - The company is gradually releasing production capacity from its specialized production lines, enhancing production efficiency [2] - The company is optimistic about the growth of guided and ammunition equipment, driven by increased foreign trade demand and ongoing model research and capacity expansion [2] Potential Catalysts - Potential catalysts include exceeding order expectations and faster-than-expected expansion progress [3] Profit Forecast and Valuation - The company is projected to have EPS of 1.10 yuan in 2025 and 1.41 yuan in 2026, with a CAGR of 21.8% from 2024 to 2026 [4] - The current valuation corresponds to a 43x P/E for 2026, with a target price of 70.61 yuan reflecting a potential upside of 18% [4]

此外，永川作业区构建全链条保供体系，高质量完成浙江油田进气点建设及大唐燃机投运，对20余个配 气站输气压力等运行参数实施精细化管控，快速处置各类运行异常，保障管网平稳高效运转;根据冬季 用气高峰、供需失衡等关键场景，细化应急处置流程、强化资源统筹调配，持续提升应急响应的速度与 精准度，为稳定供气提供坚实保障。 在此基础上，永川作业区深化联动协作，建立常态化用户用气梳理研判机制，每周全面梳理用户需求动 态及管网运行状况，精准查摆工作堵点难点，明确下一步重点任务与优化方向;每月启动复盘工作，深 度研判市场变化趋势与用户用能规律，针对性优化下月供气方案与资源调配计划，不断提升销售管理的 精细化与规范化水平。 中化新网讯12月25日，中国石油（601857）西南油气田公司重庆气矿永川采输气作业区天然气单日销量 突破1000万立方米，创造历史最佳纪录。 面对激烈的市场竞争，永川作业区锚定年度销售目标，将产能建设作为核心支撑，系统谋划、精准施策 推进重点项目落地。该作业区先后高质量完成黄202脱水站灼烧炉改造、黄202H6增压气举一体机改造 等关键工程，同步加强黄202井区核心气源的日常运维与动态监测，通过优化生产参数、 ...

Core Viewpoint - The company 康鹏科技 has provided an update regarding its stake in 中科康润, indicating that the latter's 50,000 tons/year ETO base oil project is expected to commence production in the first half of 2026, which is anticipated to positively impact 康鹏科技's performance in the coming year [1] Group 1 - 康鹏科技's stake in 中科康润 is 31.50% [1] - 中科康润's current construction capacity is 50,000 tons/year [1] - The project is expected to be operational by the first half of 2026 [1] Group 2 - 康鹏科技 has not disclosed specific contract details due to confidentiality agreements with clients [1] - The production commencement of 中科康润's project is expected to have a positive effect on 康鹏科技's revenue and profit [1]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company is acquiring a quality asset group from Future Pharmaceuticals for a total price of RMB 356 million, which includes various injectable products and their associated rights [7] - The acquisition is expected to enrich the company's product pipeline and enhance profitability, particularly in the pediatric medication sector [7] - The company has successfully defended against a lawsuit, which is anticipated to remove valuation pressure on its products [7] - The core products, including the Wuling and Bailing series, are expected to see steady growth in production and sales, supported by a planned issuance of convertible bonds for capacity expansion [7] - The company's projected net profit for 2025 is RMB 660 million, with upward adjustments for 2026 and 2027 net profits to RMB 910 million and RMB 1.13 billion, respectively [7] Financial Projections - Total revenue is forecasted to grow from RMB 2.58 billion in 2024 to RMB 4.52 billion in 2027, with a compound annual growth rate (CAGR) of approximately 16.25% [1][8] - The net profit attributable to the parent company is expected to increase from RMB 508 million in 2024 to RMB 1.13 billion in 2027, reflecting a CAGR of 24.22% [1][8] - The earnings per share (EPS) is projected to rise from RMB 0.72 in 2024 to RMB 1.61 in 2027 [1][8] - The price-to-earnings (P/E) ratio is expected to decrease from 23.83 in 2024 to 10.72 in 2027, indicating improving valuation metrics [1][8]

Core Viewpoint - Haofan Bio is progressing with the construction of its production base in Huai'an, planning to build 10 production workshops in total, with an initial phase of 5 workshops set for trial production by 2026 [1] Group 1 - The company plans to construct production lines in phases to ensure safe, rapid, and orderly capacity construction [1] - The project is currently advancing according to the established plan, with management providing estimates based on current construction progress and site conditions [1] - The company will disclose important updates regarding capacity construction in regular reports and temporary announcements to ensure fair information disclosure [1]

Group 1 - The core viewpoint of the article is that the construction of the additive manufacturing base by the company is progressing as planned, with completion expected around October 2026 [2] - The company will gradually install equipment based on market demand, with full production capacity anticipated to be achieved by 2032 [2] - The designed production capacity is based on market research, and once fully operational, it will be among the largest in the industry [2]

Core Viewpoint - Dongwu Securities report indicates that Zhaoli Pharmaceutical plans to issue convertible bonds to build capacity and develop "Wuling + X" products, supporting long-term growth [1] Group 1: Production and Capacity Expansion - The production scale of Wuling capsules and Bailing capsules is expected to continue growing in the near future [1] - The new production base and capacity expansion project are necessary measures to ensure market supply, consolidate industry position, and support strategic goals [1] Group 2: Research and Development Investment - Increased R&D investment will enrich the Wuling product series [1] - The main purpose of the fundraising project is for the development of innovative drugs and health products in the Wuling series [1] Group 3: Shareholder Returns - The company has maintained a dividend payout ratio around 80% since 2022, ranking among the top in the industry [1] - Considering the company's combination of high growth and high dividends, and the expected continuous release of core product performance in 2026, a "buy" rating is maintained [1]

Core Viewpoint - Angel Yeast has announced multiple capacity expansion plans with a total investment exceeding 1.5 billion yuan on November 22 [2] Group 1: Investment Plans - Angel Yeast's Liuzhou company plans to implement a smart manufacturing project for yeast extract products with an investment of approximately 232 million yuan [5] - Angel Yeast's Russian company intends to increase its registered capital and expand its production line to an annual capacity of 22,000 tons of yeast, with an investment of about 1.062 billion yuan [5] - Angel Yeast's park factory plans to implement a flexible smart manufacturing project for food raw materials with an annual capacity of 60,000 tons, investing around 215 million yuan [5] Group 2: Financial Performance - Angel Yeast's gross margin has been declining in recent years, with figures from 2017 to 2024 showing a decrease from 37.64% to 23.52% [5] - Research reports indicate that the growth rate of Angel Yeast's main business has slowed down as of the third quarter of 2025, primarily due to weak domestic demand [5] - In the third quarter, Angel Yeast's domestic revenue decreased by 3.5% year-on-year, while international market revenue increased by 17.7% year-on-year, indicating a short-term need for recovery in the domestic market [5]

Core Viewpoint - The company, Qijing Machinery (603677.SH), announced a capital increase of 720 million Thai Baht (approximately 160 million RMB) for its subsidiary, Qijing Industrial (Thailand) Co., Ltd., to meet customer order demands and enhance production capacity [1] Group 1 - The capital increase will be funded through the company's own resources in collaboration with its wholly-owned subsidiary, Boswei Precision Industry (Ningbo) Co., Ltd., and Xixuan Information Technology (Shanghai) Co., Ltd. [1] - The investment is aligned with the capacity construction plans of the Industrial Machinery Division and the Electrical Machinery Division [1] - The actual amount in RMB will be determined based on the exchange rate at the time of payment [1]